المؤلفون: Zaki N; Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA. nzaki@its.jnj.com., Chen LN; Department of Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA., Lane R; Department of Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA., Doherty T; Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA., Drevets WC; Department of Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA., Morrison RL; Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA., Sanacora G; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA., Wilkinson ST; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA., Popova V; Department of Neuroscience, Janssen Research & Development Belgium, Beerse, Belgium., Fu DJ; Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.

المصدر: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2023 Jul; Vol. 48 (8), pp. 1225-1233. Date of Electronic Publication: 2023 May 12.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE

مواضيع طبية MeSH: Depressive Disorder, Major*/drug therapy , Depressive Disorder, Treatment-Resistant*/drug therapy, Adult ; Humans ; Antidepressive Agents/adverse effects ; Depression ; Double-Blind Method ; Nasal Sprays ; Quality of Life ; Treatment Outcome